Daniel T Welch

US Patent:

20210087233, Mar 25, 2021

Filed:

Nov 19, 2020

Appl. No.:

16/952251

Inventors:

Christopher Bryant - Burr Ridge IL, US
Joseph William Cormier - Bethesda MD, US
Daniel G. Welch - Denver CO, US

International Classification:

C07K 7/56
C07B 59/00
A61K 9/00

Abstract:

The present disclosure relates to deuterated forms of oxytocin, carbetocin and analogs thereof. The disclosed deuterated compounds may have similar biochemical potency and selectivity as the parent compound, and, in select instances, the selective deuteration may enable substantial benefits to their overall therapeutic profile, such as reduced adverse side effects with a decreased metabolic liability, extended pharmacological effective life, enhanced subject compliance, and/or may also decrease population pharmacokinetic variability. The present disclosure also includes pharmaceutical compositions of deuterated compounds, which may be used to treat various diseases and conditions.